Submission of outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts less than Nifty Microcap 250 and 6.8 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Novelix Pharmaceuticals' board, at its meeting on March 30, 2026, approved the allotment of 11,50,000 equity shares (face value Rs. 10) at Rs. 20 per share (including a Rs. 10 premium) upon conversion of warrants held by promoter group entities. The allottees are Srinidhi Fine-Chemicals LLP (11,00,000 shares) and Narahari Belide (50,000 shares). The company received Rs. 1.72 crore as the remaining 75% of the issue price. Post-allotment, paid-up equity capital rose from Rs. 1.99 crore to Rs. 2.11 crore (2,10,85,000 shares). Additionally, Non-Executive Director Mr. Jivamohan Divakar Valluri resigned effective March 30, 2026, citing personal commitments, and will also step down from the Audit, Nomination & Remuneration, and Stakeholders' Relationship Committees.
The warrant conversion is promoter-driven and dilutes existing shareholders modestly, with paid-up capital increasing by about 5.8%. The director resignation is a routine governance change with no stated material concerns, so impact on the stock is likely neutral to mildly positive (promoter capital infusion).